| Property | Value |
|----------|-------|
| Gene Symbol | TNF |
| Full Name | Tumor Necrosis Factor Alpha |
| Chromosomal Location | 6p21.33 |
| NCBI Gene ID | 7124 |
| OMIM | 191160 |
| Ensembl ID | ENSG00000232810 |
| UniProt ID | P01375 |
| Gene Family | TNF superfamily |
| Associated Diseases | Alzheimer's Disease, Parkinson's Disease, ALS, Multiple Sclerosis, Rheumatoid Arthritis |
<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">TNF Gene</th></tr>
<tr><td><strong>Gene Symbol</strong></td><td>TNF</td></tr>
<tr><td><strong>Full Name</strong></td><td>Tumor Necrosis Factor Alpha</td></tr>
<tr><td><strong>Chromosome</strong></td><td>6p21.33</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>[7124](https://www.ncbi.nlm.nih.gov/gene/7124)</td></tr>
<tr><td><strong>OMIM</strong></td><td>191160</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>[ENSG00000232810](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000232810)</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[P01375](https://www.uniprot.org/uniprot/P01375)</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>AD, PD, ALS, MS, Rheumatoid Arthritis</td></tr>
</table>
</div>
The TNF gene encodes tumor necrosis factor alpha (TNF-α), one of the most important pro-inflammatory cytokines in the human immune system. Located on chromosome 6p21.33 within the major histocompatibility complex (MHC) region, TNF has been extensively studied for its roles in inflammation, immune regulation, and cell death pathways. TNF is produced primarily by activated macrophages and [microglia](/cell-types/microglia-neuroinflammation), but also by [neurons](/entities/neurons), [astrocytes](/entities/astrocytes), oligodendrocytes, and other cell types within the central nervous system (CNS).
TNF signals through two distinct receptors: TNFR1 (p55, TNFRSF1A) and TNFR2 (p75, TNFRSF1B). TNFR1 contains a death domain and can trigger both pro-survival NF-κB signaling and pro-apoptotic caspase activation, depending on cellular context. TNFR2 lacks the death domain and primarily mediates pro-survival and proliferative signals through NF-κB activation. This dual-receptor system allows TNF to exert context-dependent effects ranging from protective inflammation to cytotoxic cell death.
In neurodegenerative diseases, TNF has emerged as a central mediator of neuroinflammation—a pathological process characterized by chronic activation of glial cells, elevated pro-inflammatory cytokines, and consequent neuronal dysfunction and death. The recognition that neuroinflammation is not merely a secondary consequence but an active driver of neurodegeneration has placed TNF at the center of therapeutic targeting efforts. [@mc2019]
The human TNF gene spans approximately 3 kilobases and consists of 3 exons. The gene is located in the MHC class III region on chromosome 6p21.33, a region rich in immune-related genes. The promoter region contains several transcription factor binding sites, including sites for NF-κB, AP-1, and CREB, allowing for rapid induction in response to various inflammatory stimuli.
The TNF protein is synthesized as a 26 kDa transmembrane precursor (tmTNF) that can be cleaved by the metalloprotease TACE (TNF-α Converting Enzyme, also known as ADAM17) to release the soluble 17 kDa trimeric form (sTNF). Both forms are biologically active: tmTNF functions primarily in cell-to-cell contact-dependent signaling, while sTNF acts in a paracrine and endocrine manner. Importantly, reverse signaling through membrane-bound TNF (reverse signaling) allows TNF-expressing cells to receive signals from TNF receptors on neighboring cells, adding another layer of complexity to TNF biology.
The TNF trimer binds to TNFR1 or TNFR2 with high affinity. Each receptor trimerizes upon ligand binding, recruiting intracellular adaptor proteins. For TNFR1, the adaptor TRADD (TNFR1-associated death domain protein) recruits RIPK1 (receptor-interacting protein kinase 1), TRAF2/5, and activates both the canonical NF-κB pathway (leading to inflammatory gene expression) and the MAPK pathways (JNK, p38). In some contexts, TNFR1 signaling can also activate caspase-8 and trigger apoptosis. TNFR2 directly recruits TRAF1 and TRAF2, leading predominantly to NF-κB activation and pro-survival signaling.
Alzheimer's disease (AD), the most common cause of dementia, is characterized by extracellular amyloid-beta (Aβ) plaques, intracellular neurofibrillary tangles composed of hyperphosphorylated [tau](/proteins/tau) protein, synaptic loss, and progressive neuronal death. Neuroinflammation, driven by chronic activation of microglia and astrocytes, has emerged as a critical pathological component that amplifies both Aβ and tau pathology.
TNF is prominently elevated in AD brains and cerebrospinal fluid. Studies have demonstrated that TNF levels in CSF correlate with disease severity and cognitive decline. The cytokine contributes to AD pathogenesis through multiple mechanisms:
Amyloid-beta production and clearance: TNF upregulates amyloid precursor protein (APP) expression and processing through β- and γ-secretase pathways, increasing Aβ generation. TNF also impairs microglial Aβ clearance by altering the expression of Aβ-binding receptors and degrading enzymes. Additionally, TNF disrupts the blood-brain barrier (BBB), facilitating peripheral Aβ entry into the brain.
Tau pathology: TNF activates several kinases implicated in tau phosphorylation, including CDK5 and GSK-3β. Through NF-κB activation, TNF increases the expression of these kinases, promoting tau hyperphosphorylation and aggregation. TNF also exacerbates tau propagation between neurons.
Synaptic dysfunction: TNF modulates glutamate receptor trafficking and function, particularly AMPA and NMDA receptors. Excessive TNF signaling leads to synaptic pruning, reduced dendritic spine density, and impaired long-term potentiation (LTP)—a cellular correlate of learning and memory.
Neuronal death: Chronic TNF exposure sensitizes neurons to various death stimuli. TNFR1 signaling can activate both extrinsic apoptosis and necroptosis pathways. TNF also induces oxidative stress through mitochondrial dysfunction and NADPH oxidase activation.
Therapeutic strategies targeting TNF in AD include both direct TNF blockade (etanercept, infliximab, adalimumab) and indirect approaches (TACE inhibitors, TNFR1-selective antagonists). Several clinical trials have investigated TNF modulation in AD, with mixed but promising results. [@cheng2022]
Parkinson's disease (PD) is characterized by progressive loss of dopaminergic neurons in the substantia nigra pars compacta (SNc) and the presence of Lewy bodies—intracellular inclusions composed primarily of α-synuclein. Neuroinflammation, with microglial activation and elevated pro-inflammatory cytokines including TNF, is a consistent finding in PD brains and is believed to contribute to disease progression.
TNF levels are elevated in the substantia nigra, striatum, and cerebrospinal fluid of PD patients. Postmortem studies show increased TNF immunoreactivity in microglia surrounding dopaminergic neurons and within Lewy bodies. Genetic studies have identified TNF polymorphisms that modify PD risk, suggesting a causal role for TNF in disease pathogenesis.
Mechanistically, TNF contributes to dopaminergic neuron death through several pathways:
Inflammation and glial activation: TNF is a potent activator of microglia, creating a feed-forward loop of neuroinflammation. Activated microglia release additional pro-inflammatory cytokines (IL-1β, IL-6), reactive oxygen species (ROS), and nitric oxide (NO), creating a toxic microenvironment for dopaminergic neurons.
Oxidative stress: TNF upregulates NADPH oxidase and inducible nitric oxide synthase (iNOS), generating ROS and reactive nitrogen species that damage neurons. TNF also impairs mitochondrial function, reducing ATP production and increasing susceptibility to metabolic stress.
Mitochondrial dysfunction: TNF activates pathways that disrupt mitochondrial integrity, including JNK-mediated phosphorylation of mitochondrial proteins and Drp1-dependent fission. Mitochondrial dysfunction is central to PD pathogenesis, and TNF amplifies this pathway.
α-synuclein pathology: TNF can increase α-synuclein expression and aggregation through NF-κB-dependent transcriptional activation. Conversely, α-synuclein can activate microglia, creating another feed-forward loop.
TNF-blocking therapies have shown protective effects in animal models of PD. Etanercept, a TNF receptor fusion protein, reduces microglial activation and dopaminergic neuron loss in MPTP and 6-OHDA models. Several clinical trials have evaluated TNF modulation in PD, with ongoing investigations exploring neuroprotective effects. [@barnum2020] [@tizek2022]
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by progressive loss of upper and lower motor neurons. Neuroinflammation, involving both microglia and astrocytes, is a hallmark of ALS pathology. TNF is prominently elevated in ALS brains, CSF, and peripheral blood, with levels correlating with disease progression and severity.
Microglial TNF production contributes directly to motor neuron injury. TNF levels in the spinal cord correlate with disease progression in SOD1 mouse models, and TNF knockout or blockade extends survival. The mechanisms include:
Excitotoxicity: TNF potentiates glutamate-induced toxicity by upregulating AMPA receptor GluR1 subunit expression and promoting synaptic insertion of calcium-permeable AMPA receptors. This amplifies excitotoxic motor neuron death.
Oxidative stress: TNF increases NADPH oxidase and iNOS expression in microglia and astrocytes, generating ROS that damage motor neurons.
Apoptosis and necroptosis: TNF can directly trigger motor neuron death through TNFR1 death domain signaling, activating both caspase-8-mediated apoptosis and RIPK1/3-mediated necroptosis.
Glial crosstalk: TNF propagates neuroinflammation between microglia and astrocytes, creating a self-sustaining toxic environment.
Clinical trials with TNF antagonists in ALS have shown mixed results. The complexity of TNF signaling—with both neurotoxic and potentially neuroprotective effects—poses challenges for therapeutic targeting. [@liao2018]
Multiple sclerosis (MS) is an autoimmune demyelinating disease of the CNS in which TNF plays a central pathogenic role. TNF is elevated in MS lesions, CSF, and serum, and its levels correlate with disease activity. TNF promotes demyelination, blood-brain barrier breakdown, and immune cell infiltration into the CNS.
The success of TNF-blocking therapies (etanercept, infliximab) in rheumatoid arthritis and inflammatory bowel disease led to their evaluation in MS—but paradoxically, some patients worsened, suggesting context-dependent effects of TNF in CNS autoimmunity. This highlights the complexity of TNF biology and the importance of understanding both protective and pathogenic roles.
Huntington's Disease (HD): TNF is elevated in HD brains and cerebrospinal fluid. TNF contributes to striatal neuron death through NF-κB activation, oxidative stress, and excitotoxicity. TNF polymorphisms modify disease age of onset.
Frontotemporal Dementia (FTD): Elevated TNF has been reported in FTD brains, particularly in cases with TDP-43 pathology. TNF may contribute to neuroinflammation in FTD subtypes.
Prion Diseases: TNF is upregulated in prion disease brains and may contribute to neuronal death and disease progression.
The NF-κB pathway is the primary signaling cascade activated by TNF receptor engagement. Upon TNF binding, TNFR1 recruits TRADD, TRAF2, and RIPK1, forming Complex I. This complex activates the IKK complex (IKKα, IKKβ, IKKγ/NEMO), which phosphorylates IκBα, targeting it for ubiquitination and degradation. This releases NF-κB dimers (p50/p65) to translocate to the nucleus and induce transcription of inflammatory genes.
TNF-induced NF-κB activation leads to:
TNF activates three major MAPK pathways:
When NF-κB survival signaling is inhibited or overwhelmed, TNF can trigger cell death:
In the healthy CNS, TNF is expressed at low levels primarily by:
In the periphery, TNF is produced by:
Several TNF-blocking agents are approved for clinical use in autoimmune diseases:
Despite promise, TNF-targeted therapy faces challenges in neurodegenerative diseases:
From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
The following diagram shows the key molecular relationships involving TNF Gene discovered through SciDEX knowledge graph analysis: